We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Regeneron is humming along on the strength of flagship eye med Eylea and fast-launching immunology drug Dupixent. Now, the drugmaker is investing $800 million in its New York operations to keep up with the growth.